Lilly Delivers Sixth Consecutive Quarter of Double-Digit Sales Growth
July 22, 2004
Newer Products Generated $350 Million in Second-Quarter Sales
Eli Lilly and Company (NYSE: LLY) announced financial results for the second quarter of 2004.
Second-Quarter Highlights
- Sales increased 15 percent, to $3.556 billion, driven primarily by increased worldwide sales of Zyprexa®, Strattera®, Evista®, Forteo®, and Gemzar®.
- Newer products-Alimta®, Cialis®, Forteo®, Strattera, Symbyax™ and Xigris® - contributed $350.4 million to second-quarter sales in 2004 and accounted for 10 percent of total sales.
- Net income decreased 5 percent, to $656.9 million, and diluted earnings per share decreased 6 percent, to $.60, due primarily to a pretax charge of $108.9 million for asset impairments.
- Excluding the second-quarter-2004 asset-impairment charge, net income and diluted earnings per share increased 7 percent and 6 percent, to $738.7 million and $.68, respectively.
PDF of Full News Release
To view a PDF (60 KB) of the full news release, please visit http://www.lilly.com/q204Lilly_earnings.pdf.
Webcast of Conference Call
As previously announced, investors and the general public can access a live webcast of the second-quarter 2004 earnings conference call by visiting http://investor.lilly.com/MediaRegister.cfm?MediaID=12172. The conference call will be held today from 9:30 a.m. to 10:30 a.m. EDT and will be available for replay via the Web site through Aug. 19, 2004.
Important Note: You must have Acrobat Reader version 4.0 or higher installed to view these files. If you have an earlier version installed, an update is available from the Adobe Acrobat Reader download site.